

Genotyping of *cagA* and the intermediate region of *vacA* in strains of *Helicobacter pylori* isolated from Colombian adult patients and associations with gastric diseases

M. Camila Melo-Narváez,¹ Diana F. Rojas-Rengifo,¹ Luisa F. Jiménez-Soto,² María del Pilar Delgado,¹ Belén Mendoza de Molano,³ José Fernando Vera-Chamorro,³ Carlos Jaramillo.¹

¹ Molecular Diagnosis and Bioinformatics Laboratory (LDMB - Laboratorio de Diagnóstico Molecular y Bioinformática) at University of the Andes in Bogotá, Colombia

² Max von Pettenkoffer Institute for Hygiene and Clinical Microbiology of the Department of Bacteriology at LMU München. Munich, Germany.

³ Division of Gastroenterology and Digestive Endoscopy at the Fundación de Santa Fe de Bogotá. Bogotá, Colombia.

Corresponding author: María Camila Melo Narváez
cami93melo@gmail.com

Received: 28-09-17
Accepted: 13-04-18

Abstract

Objective: This study characterizes the diversity of *cagA* and *vacA* virulence genes in Colombian patients to determine possible associations between them and the severity of endoscopic findings. It considers all four genotypes reported for the *vacA* gene (s, m and i). **Materials and methods:** *Helicobacter pylori* was detected in biopsies of 62 patients through culturing and by molecular methods. Genotypes of *cagA* and *vacA* (*m/i/s*) were determined by PCR and sequencing. **Results:** One hundred twenty four strains from 62 patients were isolated. Of these, 48.5% (n = 48) were *vacA* *s2/m2/i2* - *cagA* (-) which were mostly found in patients with follicular gastritis; 32.3% (n = 32) were *vacA* *s1/m1/i1*-*cagA* (+) which were mostly found in patients with follicular gastritis, chronic gastritis and possible metaplasia. Significant associations were found between the presence of *cagA* and the *vacA* *s1/m1/i1* genotype and the absence of *cagA* and the *vacA* *s2/m2/i2* genotype ($p < 0.001$). No significant association was found between the severity of endoscopic findings and the *cagA*-*vacA* status of the strains. **Conclusion:** We found a low prevalence of *cagA* (+) strains, the *cagA*-*vacA* status is not a predictor of risk in this population. Moreover, the presence of heterogeneous infections without tropism suggests a need for biopsies from both the corpus and the antrum of the stomach in routine clinical practice.

Keywords

vacA subtypes, *cagA*, *Helicobacter pylori*, Colombia.

INTRODUCTION

Helicobacter pylori are spiral-shaped, microaerophilic gram-negative bacteria that infect more than 50% of the world's population. (1) The infection has been associated with diseases such as gastritis, peptic ulcers, MALT (mucosa-associated lymphoid tissue) lymphoma and gastric adenocarcinoma. (2) *H. pylori*'s most important virulence factors are the cytotoxin-associated gene A (*CagA*) and vacuolating cytotoxin A (*VacA*). (3) Depending on whether the *cagA* gene is present, strains are classified as positive (type I) which is more virulent due to the visible gastric damage induced, and negative (type II) which is less virulent and acts more like commensal bacteria than pathogens. (4)

The *VacA* protein causes a series of alterations in human gastric cells that include formation of cytoplasmic vacuoles, (5, 6) permeabilization of the plasma membrane, (6) mitochondrial secretion of cytochrome c, (7) mitochondrial fragmentation, (8) activation of mitogen-activated kinases. (9) and induction of autophagy. (6) It has been classified as an immunomodulatory protein. (6, 10) The *vacA* gene has 3 polymorphic regions that are involved in the development of the disease: the signal region (s), the intermediate region (i), and the middle region (m). (2, 3, 6, 11-13)

The s region is involved in the efficiency of channel formation, and the m region affects tropism towards host cells. (3). Although the i region has only recently been described, it has been observed that the vacuolating activity of variant *VacA* *i1* is stronger than that of subtype *VacA* *i2*. (3, 6) Some analyses

of the nucleotide and amino acid sequence of this gene have revealed polymorphisms grouped in clusters A, B and C. Of these, the amino acids in clusters B and C are responsible for the vacuolating activity of the protein. (11)

To classify a strain as *i1*, *i2* or *i3*, the amino acid sequence is compared with sequences of reference strains (60190 for *i1* and Tx30a for *i2*). The *i3* variant of *vacA* includes strains whose B cluster is similar to that of *i1* and whose C cluster is similar to that of *i2*. (11) Different combinations of the 3 regions have been described: *vacA s1/m1* strains have vacuolating activity and pose greater risk of gastric atrophy and adenocarcinoma than do the less virulent *vacA s2/m2* strains. (11, 12) *vacA i1* strains have also been associated with gastric adenocarcinoma. (2, 11, 12)

Recently, epidemiological studies have suggested that the interaction between *cagA* and *vacA* virulence factors, (6) factors of host susceptibility such as differences between men and women, (14-16) and environmental factors modulate development of the disease. (4, 12)

Several genotyping studies of *H. pylori* isolates from different Colombian populations have been published. Taking into account that the intermediate region can change the behavior of the toxin, this study complements data on genotyping of these two toxins including characterization of this region of *vacA* in isolates from a Colombian Andean population with gastric diseases of varying severity and evaluates correlations between genotype and the development of gastric disease.

MATERIALS AND METHODS

Patients and Study Population

We included 62 patients from Bogotá, Colombia who were over the age of 18 years, who were infected with *H. pylori*, and who had gastric symptoms and indications for endoscopy. Patients who had ingested proton pump inhibitors (PPI) within the 15 days prior to the procedure, antacids within the 12 hours prior to the procedure, or antibiotics in month prior to the procedure were excluded. Also excluded were patients suffering from cardiovascular and respiratory diseases, cancer patients who had undergone radiation therapy or chemotherapy in the six months prior to the procedure, and patients with coagulopathies or amyloidosis.

Strains and DNA Purification

Biopsies were macerated and a 10⁻¹ dilution was seeded on GC agar (Oxoid, Germany) supplemented with cholesterol (1X, Gibco) and DENT (Oxoid, Germany). (17) They were incubated at 37° C in a controlled atmosphere with 10% carbon dioxide (CO₂) for four to ten days. The

Quick-gDNA Miniprep kit (Zymo Research, California, United States) was used to extract DNA in accordance with the manufacturer's instructions. The strains were selected by culture and confirmed as *H. pylori* by polymerase chain reaction (PCR) of the 23S gene with the HPY-S and HPY-A primers previously reported. (18)

Detection of *cagA*

PCR was performed with the primers designed in this study and the previously reported protocol as modified and described in Table 1. (19) The PCR had a final volume of 25 µL with GoTaq Green Master Mix 1X (Promega, Wisconsin, United States) and 0.25 mM of each primer. Visualization was performed on 1.5% agarose gels.

vacA Genotyping

The 3 polymorphic regions of the *vacA* gene were characterized by means of PCR with a final volume of 25 µL containing GoTaq Green Master Mix 1X (Promega, Wisconsin, United States) and 0.25 mM of the corresponding primers for each region according to the previously reported protocols as modified in this study (Table 1).

For the visualization of the products, 2% agarose gels were used for the *m* and *i* regions and 10% polyacrylamide was used for the *s* region. (29: 1) Polyacrylamide gels were stained with a 3X GelRed solution (15 µL of Gelred 10,000X and 5 mL of sodium chloride [NaCl] 1M) for 1 hour under constant stirring at room temperature.

Samples that tested positive for both subtypes (*vacA i1* and *i2*) were sequenced (Macrogen, Seoul, Korea). Sequence analysis was performed with CLC Genomics Workbench 10, and amino acid sequences were compared with reference sequences 60190 (GenBank No. U05676) and Tx30a (GenBank No. U29401). Strains were defined as *i3* when the B cluster was similar to that of reference strain *i1* and the C cluster was similar to reference strain *i2*. (11)

Statistical Analysis

Fisher's exact test was used to determine possible associations between the *cagA* status and the *vacA* genotype of the strains, and a generalized linear model was used to determine which variables had significant associations. The same statistical analysis was performed for polymorphic regions of the *vacA* gene and *cagA* status and between and among *cagA* status, *vacA* gene subtypes and severity of endoscopic findings. A chi squared (χ^2) test was used to determine associations between the patient's sex and *cagA* status, and the patient's sex and severity of endoscopic findings. Endoscopic findings were classified as either

Table 1. Primers and protocol used for amplification of *cagA* and *vacA*

Region	Primer	Sequence	Product size (bp)	PCR protocol
<i>cagA</i>	DR1	GATAACAGGCAAGCTTTGAGG	179	One 4 min cycle at 94° C, Thirty-two cycles at 94° C for 30 s, 52° C for 30 s and 72° C for 1 min, and one cycle of 72° C for 10 min (19)
	DR2	CTGCAAAAGATTGTTTGGCAGA		
<i>vacA s</i> (19)	Va1-F	ATGGAAATACAACAAACACAC	s1: 259	One 4 min cycle at 94° C, Thirty cycles at 94° C for 30 s, 58° C for 30 s and 72° C for 1 min, and one cycle of 72° C for 10 min (19)
	Va1-R	CTGCTTGAATGC GCCAAAC	s2: 289	
<i>vacA m1</i> (19)	Va3-F	GGTCAAATGCGGTCATGG	290	One 4 min cycle at 94° C, Thirty cycles at 94° C for 30 s, 55° C for 30 s and 72° C for 1 min, and one cycle of 72° C for 10 min (19)
	Va3-R	CCATTGGTACTCT GTAGAAAC		
<i>vacA m2</i> (19)	Va4-F	GGAGCCCCAGGAAACATTG	352	
	Va4-R	CATAACTAGCGTCTTGACAC		
<i>vacA i1</i> (2)	VacF1	GTTGGGATTGGGGGAATGCCG	426	One 4 min cycle at 95° C, Thirty-five cycles at 95° C for 30 s, 55° C for 60 s and 72° C for 30 s, and one cycle of 72° C for 5 min (2)
	C1R	TTAATTTAACGCTGT TTGAAG		
<i>vacA i2</i> (2)	VacF1	GTTGGGATTGGGGGAATGCCG	432	
	C2R	GATCAACGCTCTGAT TTGA		

bp: base pairs

mild gastric disease and severe gastric disease (Table 2). R software (20) was used for analysis and a p value <0.05 was considered significant.

RESULTS

Patients and Isolation of *H. pylori*

We analyzed 124 *H. pylori* strains from 62 patients who had a variety of symptoms (Table 3). Their average age was 50.2 ± 16.2 years, and the male-female ratio was 1.48/1.

Genotyping of *cagA* and *vacA*

PCR with corresponding primers established that 52 (48.1%) of the 124 strains analyzed were positive for *cagA*. No significant associations were found between the severity of endoscopic findings and the presence of *cagA* (χ^2 , $p > 0.05$) (Table 4). There were also no significant associations between the sex of the patients and the presence of *cagA* (χ^2 , $p > 0.05$), between the severity of the endoscopic findings and sex (Fisher's exact test, $p > 0.05$), or between the severity of the endoscopic findings and the presence of *cagA* (χ^2 , $p > 0.05$) (Table 4).

In the case of *vacA*, 16 strains were discarded ($n = 8$ patients) because it was not possible to determine the genotype for the *s* region in three cases (37.5%), the *m* region in three cases (37.5%), the *s* region in one case (12.5%) and for all three regions in one other case (12.5%). Of the remaining 108 strains, fifty strains were *s1*, fifty-eight were *s2*, forty-one were *m1*, and sixty-seven were *m2*. Thirty-four strains were *i1* and 55 *i2*. Nineteen of the samples sequenced (17.6%) showed amplification for both *vacA i1* and *vacA*

Table 2. Classification of endoscopic findings*

Severity	Endoscopic findings (%)	Average age (years)
Mild	Suspected gastroparesis (1.61)	89
	Chronic and acute gastritis (12.9)	53.7 ± 9.66
	Chronic gastritis (16.1)	58.8 ± 17.3
	Follicular gastritis (27.4)	39.8 ± 12.4
	Petechial gastritis (4.84)	48.6 ± 24.1
Severe	Erosive gastritis (17.7)	52.5 ± 14.6
	Atrophic gastritis (6.45)	58.5 ± 19.3
	Gastric ulcer (1.61)	58
	Suspicion of metaplasia (11.2)	45.1 ± 13.1

* Prevalence of endoscopic findings is shown with classification as either mild or severe according to medical criteria.

Table 3. Distribution of gastric symptoms reported by patients*

Symptom	Number of Patients (%)
Epigastric pain	37 (59.7)
Regurgitation	32 (51.6)
Abdominal pain	31 (50.0)
Sternal pain	8 (12.9)
Dysphagia	6 (9.68)
Postprandial filling	10 (16.1)
Loss of appetite	1 (1.61)
Weight loss	9 (14.5)
Heartburn	28 (45.2)
Reflux	32 (51.6)

* Patients reported various gastric symptoms before digestive endoscopy.

i2 subtypes (GenBank No. MF457450 to MF457477). Of these, four were classified as *i1*, three as *i2*, three as *i3* and nine as *i1i2*. The last group was eliminated in subsequent analyses. No significant associations were found the severity of the endoscopic findings and either *vacA* subtypes or the full *vacA* genotype ($\chi^2, p > 0.05$) (Table 4).

Twenty-eight strains (22.6%) were discarded from the evaluation of the relationship between the two genes because they had different genotypes of *cagA* and *vacA* between antrum and corpus. No significant tropism or correlation was found between the genotype and location within the stomach of these strains. However, a significant association was found between *cagA* status and the *vacA* gene subtypes looked at separately (Fisher's exact test, $p < 0.05$) (Figure 1) and combined as follows: *s1/m1/i1-cagA* positive (32.3%), *s1/m2/i1-cagA* positive (2.02%) and *s1/m2/i2* (7.07%). Of these 71.4% were *cagA* positive, 2.02% were *s1/m1/i3-cagA* positive, 1.01% were *s1/m2/i3-cagA* positive, 2.02% were *s2/m1/i1-cagA* positive, and 48.5% were *s2/m2/i2-cagA* negative (Fisher's exact test, $p < 0.001$, generalized linear model binomial $p < 0.05$). In addition, all *vacA i3* strains were *cagA* positive.

DISCUSSION

This study characterizes the diversity of virulence genes *cagA* and *vacA* in Colombian patients to determine possi-

ble associations between these two genes and the severity of the endoscopic findings. It considers all three genotypes reported for the *vacA* gene: *s*, *m* and *i*. The combination of genetic variability, host factors and environmental factors plays a fundamental role in the development of pathologies during *H. pylori* infections. (3, 4, 6, 12, 21-23). It has been reported that patients infected with *vacA s1/m1/i1-cagA* (+) strains are at greater risk of developing gastric carcinomas than are patients infected with the less virulent *vacA s2/m2/i2-cagA* (-). (2, 4, 11-13, 19, 24)

In the Colombian population studied, a prevalence of 48.1% was found for infections with *cagA* positive strains. This is lower than previously reported in studies conducted in Bogotá, Colombia which found a prevalence of 73%, (24) but it is similar to that reported in patients from Tolima, Colombia for whom prevalence of *cagA* positive strains was 43%. (25) The prevalence reported here also differs from those found in other regions of the world such as Senegal (73.3%), (26) the Middle East (100%), the United States (80%), and Western Europe and Latin America (60% to 70%). (11) This is probably due to the fact that the selected population was of medium and high socioeconomic class since it has been seen that the prevalence of the infection is higher in lower socioeconomic levels with poor sanitary conditions. (27, 28)

This study also shows that 22.6% of the patients were infected with two different strains of either or both *cagA*

Table 4. Association between severity of endoscopic findings, *cagA* status and polymorphic regions of the *vacA* gene*

Severity of endoscopic finding		Mild n (%)	Severe n (%)
<i>cagA</i>	Positive	11 (27.5)	6 (15.0)
	Negative	15 (37.5)	8 (20.0)
<i>vacA</i>	<i>s1</i>	10 (25.0)	8 (20.0)
	<i>s2</i>	16 (40.0)	6 (15.0)
	<i>m1</i>	9 (22.5)	6 (15.0)
	<i>m2</i>	17 (42.5)	8 (20.0)
	<i>i1</i>	10 (25.0)	6 (15.0)
	<i>i2</i>	16 (40.0)	8 (20.0)
	<i>s1/m1/i1</i>	8 (20.0)	6 (15.0)
	<i>s1/m2/i1</i>	1 (2.50)	0 (0.0)
	<i>s1/m2/i2</i>	1 (2.50)	2 (5.0)
	<i>s2/m1/i1</i>	1 (2.50)	0 (0.0)
	<i>s2/m2/i2</i>	15 (37.5)	6 (15.0)

* No significant relationships were found between the severity of endoscopic findings and *cagA* or *vacA* status. Patients who had different genotypes in the gastric antrum and corpus were excluded. Fisher's exact test and a generalized linear binomial model ($p > 0.05$) were used.




Figure 1. Association between *cagA* status and *vacA* subtypes. There is a significant association between *cagA* status and *vacA* subtypes. Patients with *cagA* status or *vacA* genotypes that differed between the antrum and corpus were excluded. Fisher's exact test and a generalized linear binomial model ($p < 0.001$) were used.

and *vacA* in the gastric antrum and corpus but without any tropism. It is possible that these patients have been infected on more than one occasion by different strains of *H. pylori* because the prevalence of multiple infections seems to be higher in places like Colombia where the risk of *H. pylori* infection is high. (29, 30) The presence of these types of infections reaffirms the need to routinely take biopsies from both the corpus and antrum.

The relationship between the presence of *cagA* and the *vacA s1* genotype has been described by several authors. (31, 32) In this study, 68.1% of positive *cagA* strains were *vacA s1/m1/i1* and only 6.4% were *vacA s2/m2/i2*. Thus, the *vacA s1/m1/i1* genotype has a significant association with the presence of the *cagA* gene. In the case of *vacA s1/m2* strains, it has been observed that whether the prevalence of type *i1* is greater than the prevalence of *i2* strains and vice versa depends on the geographical region. (2, 26) A low prevalence of the *vacA s2/m1* combination was found in this study. This agrees with previous findings which suggests that the low prevalence of this genotype may be explained by negative selection of this subtype because it is unfavorable for microorganisms. (26)

In addition, this study describes intermediate region of the *vacA* gene strains in strains circulating in this Colombian population. Almost all of the *vacA s1/m1* strains (94.4%) were *i1* and almost all the *vacA s2/m2* strains were *i2*. This agrees with what was reported in the first description of the intermediate region. (2) The majority of strains analyzed were *vacA i2*, and only three patients were found to be infected by *vacA i3* strains defined as those with cluster B similar to *i1* and cluster C similar to type *i2*. (11) The *i3* variant could reflect a recombination process between type *i1* and *i2* strains. (6, 11) The clinical or pathological importance of this variant remains unknown, and our study found no significant associations with endoscopic findings. However, all *vacA i3* strains were *cagA* positive. A larger sample of patients infected with *i3* strains is needed to gain a better understanding of the nature of this genotype and the development of the disease in these patients.

In contrast to the significant associations between the *vacA s1/m1/i1-cagA (+)* genotype and some severe digestive diseases such as atrophic gastritis, ulcers and gastric adenocarcinoma observed in other studies, (33) no significant associations were found between the *cagA-vacA* status of the strains and the severity of the endoscopic findings in this study despite the fact that most of the strains isolated were *vacA s2/m2/i2-cagA (-)* from patients who mostly presented follicular gastritis (Figure 2). This could be the result of the small sample sizes of each of the categories of

severity of endoscopic findings (mild or severe) and the high prevalence of type II strains in the patients. For this reason, the *vacA* genotype cannot be used to identify high-risk patients in the study population.

In conclusion, this study provides new information on the prevalence of *cagA* and *vacA* virulence factors, and their association with endoscopic findings. Studies conducted on the west coast and in the southern Colombian Andes differ from the findings of this investigation highlighting the need to increase the number of studies that compare different regions and Colombian populations. (34, 35) This is especially true since the data published in Colombia show great variations in the presence of genetic markers of pathogenicity and their correlations with the severity of gastric pathologies.

On the other hand, recent studies have indicated that *H. pylori* strains in the Colombian population originating in the European line (HpEurope) have evolved independently. (36) It is likely that molecular mechanisms typically associated with severe gastric diseases associated *H. pylori* behave differently in the Colombian population thanks to the different ancestries present. (37) If the bacterium-host relationship is considered, it is possible that the lack of correlations between *cagA* and *vacA* and the pathology of the infection relative to the findings of other studies could be thoroughly investigated only if the ancestral distributions in the various regions of Colombia.

Acknowledgements

The authors would like to thank Sebastián Posada MD, Laura Camila Zuluaga MD, Daniela Campaz, MD and Manuel Arrieta MD for their help in the collection of samples and management of the database. We would also like to thank Verónica Arévalo Jaimes for her help with molecular processing and identification of strains by means of PCR of the 23S region. We thank Professor Adolfo Amézquita and Cindy Ulloa for their support in statistical analysis.

Financing

This study was supported by the Faculty of Sciences of the Universidad de los Andes through the project entitled "Factors of virulence *cagA* and *vacA* of strains of *H. pylori* and its relationship with pathology in symptomatic Colombian adult patients" code P16.160322.001/01-BIO01 (according to a decision of the Research Projects Committee on 12/11/2015) and by DFG research grant (JI 221/1-1) for LFJ-S.




Figure 2. Relative prevalence of endoscopic findings according to the genotype of *H. pylori* strains isolated in these patients. 52.5% of patients were infected with *H. pylori* *vacA* *s2/m2/i2-cagA* negative strains which were mostly related to follicular gastritis. Patients who had different *cagA* or *vacA* genotypes in the antrum and corpus were excluded. Suspicion of metaplasia (SM), gastric ulcer (UG), atrophic gastritis (GA), petechial gastritis (GP), erosive gastritis (GE), chronic gastritis (GC) and follicular gastritis (GF).

REFERENCES

1. Peleteiro B, Bastos A, Ferro A, et al. Prevalence of *Helicobacter pylori* infection worldwide: a systematic review of studies with national coverage. *Dig Dis Sci.* 2014;59(8):1698-709. doi: 10.1007/s10620-014-3063-0.
2. Rhead JL, Letley DP, Mohammadi M, et al. A new *Helicobacter pylori* vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer. *Gastroenterology.* 2007;133(3):926-36. doi: 10.1053/j.gastro.2007.06.056.
3. Jones KR, Jang S, Chang JY, et al. Polymorphisms in the intermediate region of *VacA* impact *Helicobacter pylori*-induced disease development. *J Clin Microbiol.* 2011;49(1):101-10. doi: 10.1128/JCM.01782-10.
4. García CA, Barra TR, Delgado SC, et al. Genotipificación de aislados clínicos de *Helicobacter pylori* en base a genes asociados a virulencia *cagA*, *vacA* y *babA2*: primer aislamiento de una cepa *babA2* positiva en pacientes chilenos. *Rev Médica Chile.* 2006;134(8):981-8. doi: 10.4067/S0034-98872006000800006.
5. Cover TL, Blaser MJ. Purification and characterization of the vacuolating toxin from *Helicobacter pylori*. *J Biol Chem.* 1992;267(15):10570-5.
6. Kim I-J, Blanke SR. Remodeling the host environment: modulation of the gastric epithelium by the *Helicobacter*

- pylori vacuolating toxin (VacA). *Front Cell Infect Microbiol.* 2012;2:37. doi: 10.3389/fcimb.2012.00037.
7. Foo JH, Culvenor JG, Ferrero RL, et al. Both the p33 and p55 Subunits of the *Helicobacter pylori* VacA Toxin Are Targeted to Mammalian Mitochondria. *J Mol Biol.* 2010;401(5):792-8. doi: 10.1016/j.jmb.2010.06.065.
 8. Jain P, Luo Z-Q, Blanke SR. *Helicobacter pylori* vacuolating cytotoxin A (VacA) engages the mitochondrial fission machinery to induce host cell death. *Proc Natl Acad Sci U S A.* 2011;108(38):16032-7. doi: 10.1073/pnas.1105175108.
 9. Nakayama M, Kimura M, Wada A, et al. *Helicobacter pylori* VacA Activates the p38/Activating Transcription Factor 2-mediated Signal Pathway in AZ-S21 Cells. *J Biol Chem.* 2004;279(8):7024-8. doi: 10.1074/jbc.M308898200.
 10. Boncristiano M, Paccani SR, Barone S, et al. The *Helicobacter pylori* vacuolating toxin inhibits T cell activation by two independent mechanisms. *J Exp Med.* 2003;198(12):1887-97. doi: 10.1084/jem.20030621.
 11. Chung C, Olivares A, Torres E, et al. Diversity of vacA intermediate region among *Helicobacter pylori* strains from several regions of the world. *J Clin Microbiol.* 2010;48(3):690-6. doi: 10.1128/JCM.01815-09.
 12. Ferreira RM, Machado JC, Letley D, et al. A novel method for genotyping the *Helicobacter pylori* vacA Intermediate region directly in gastric biopsy specimens. *J Clin Microbiol.* 2012;50(12):3983-9. doi: 10.1128/JCM.02087-12.
 13. González-Rivera C, Algood HMS, Radin JN, et al. The intermediate region of *Helicobacter pylori* vacA is a determinant of toxin potency in a jurkat t cell assay. *Infect Immun.* 2012;80(8):2578-88. doi: 10.1128/IAI.00052-12.
 14. Agah S, Khedmat H, Ghamar-Chehred ME, et al. Female gender and *Helicobacter pylori* infection, the most important predisposition factors in a cohort of gastric cancer: a longitudinal study. *Casp J Intern Med.* 2016;7(2):136-41.
 15. Naja F, Kreiger N, Sullivan T. *Helicobacter pylori* infection in Ontario: Prevalence and risk factors. *Can J Gastroenterol.* 2007;21(8):501-6. doi: 10.1155/2007/462804.
 16. Zhu Y, Zhou X, Wu J, et al. Risk factors and prevalence of *Helicobacter pylori* infection in persistent high incidence area of gastric carcinoma in Yangzhong City. *Gastroenterol Res Pract.* 2014;2014:e481365.
 17. Jiménez-Soto LF, Rohrer S, Jain U, et al. Effects of cholesterol on *Helicobacter pylori* growth and virulence properties in vitro. *Helicobacter.* 2012;17(2):133-9. doi: 10.1111/j.1523-5378.2011.00926.x.
 18. Ménard A, Santos A, Mégraud F, et al. PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with *Helicobacter pylori* resistance to clarithromycin. *Antimicrob Agents Chemother.* 2002;46(4):1156-7. doi: 10.1128/AAC.46.4.1156-1157.2002.
 19. Secka O, Antonio M, Berg DE, et al. Mixed infection with cagA positive and cagA negative strains of *Helicobacter pylori* lowers disease burden in The Gambia. *PLoS ONE.* 2011;6(11):e27954. doi: 10.1371/journal.pone.0027954.
 20. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing [internet] 2008 [acceso el 24 de noviembre de 2016]. Disponible en: <http://www.R-project.org>.
 21. Argent RH, Thomas RJ, Letley DP, et al. Functional association between the *Helicobacter pylori* virulence factors vacA and cagA. *J Med Microbiol.* 2008;57(2):145-50. doi: 10.1099/jmm.0.47465-0.
 22. Jang S, Jones KR, Olsen CH, et al. Epidemiological link between gastric disease and polymorphisms in vacA and cagA. *J Clin Microbiol.* 2010;48(2):559-67. doi: 10.1128/JCM.01501-09.
 23. Yamazaki S, Yamakawa A, Okuda T, et al. Distinct Diversity of vacA, cagA, and cagE Genes of *Helicobacter pylori* Associated with Peptic Ulcer in Japan. *J Clin Microbiol.* 2005;43(8):3906-16. doi: 10.1128/JCM.43.8.3906-3916.2005.
 24. Quiroga AJ, Cittely DM, Bravo MM. Frecuencia de los genotipos babA2, oipA y cagE de *Helicobacter pylori* en pacientes colombianos con enfermedades gastroduodenales. *Biomédica.* 2005;25:325-34. doi: 10.7705/biomedica.v25i3.1357.
 25. Molina Delgado A, Jaramillo Henao C, Delgado Perafán M, et al. Detección y genotipificación de *Helicobacter pylori* sobre la base de los genes ADNr 16S y el gen asociado a citotoxina (cagA) y posible asociación con enfermedades gastrointestinales. *Rev ista Cubana de Medicina Tropical.* 2008;60:105-10.
 26. Basso D, Zambon C-F, Letley DP, et al. Clinical relevance of *Helicobacter pylori* cagA and vacA gene polymorphisms. *Gastroenterology.* 2008;135(1):91-9. doi: 10.1053/j.gastro.2008.03.041.
 27. Parente JML, da Silva BB, Palha-Dias MPS, et al. *Helicobacter pylori* infection in children of low and high socioeconomic status in northeastern Brazil. *Am J Trop Med Hyg.* 2006;75(3):509-12.
 28. Ramírez Ramos A, Chinga Alayo E, Mendoza Requena D, et al. Variación de la prevalencia del *H. pylori* en el Perú período (1985-2002), en una población de nivel socioeconómico medio y alto. *Rev Gastroenterol Perú.* 2003;23(2):92-8.
 29. Mendoza-Elizalde S, Cortés-Márquez AC, Giono-Cerezo S, et al. Analysis of the genotypic diversity of strains of *Helicobacter pylori* isolated from pediatric patients in Mexico. *Infect Genet Evol.* 2015;29:68-74. doi: 10.1016/j.meegid.2014.11.002.
 30. Pinto-Ribeiro I, Ferreira RM, Batalha S, et al. *Helicobacter pylori* vacA genotypes in chronic gastritis and gastric carcinoma patients from Macau, China. *Toxins (Basel).* 2016;8(5). pii: E142. doi: 10.3390/toxins8050142.
 31. Atherton JC, Cao P, Peek RM Jr, et al. Mosaicism in vacuolating cytotoxin alleles of *Helicobacter pylori*. Association of specific vacA types with cytotoxin production and peptic ulceration. *J Biol Chem.* 1995;270(30):1-7. doi: 10.1074/jbc.270.30.17771.
 32. Nagiyev T, Yula E, Abayli B, et al. Prevalence and genotypes of *Helicobacter pylori* in gastric biopsy specimens from patients with gastroduodenal pathologies in the Cukurova

- Region of Turkey. *J Clin Microbiol.* 2009;47(12):4150-3. doi: 10.1128/JCM.00605-09.
33. Breurec S, Michel R, Seck A, et al. Clinical relevance of *cagA* and *vacA* gene polymorphisms in *Helicobacter pylori* isolates from Senegalese patients. *Clin Microbiol Infect.* 2011;18(2):153-9. doi: 10.1111/j.1469-0691.2011.03524.x.
 34. Bravo MM, Trujillo E, Quiroga A, et al. Genotipificación de *Helicobacter pylori* en individuos de dos regiones de Colombia con riesgo de cáncer gástrico opuesto. *Rev Colomb Cancerol.* 2013;17(4):178-9.
 35. Nogueira C, Figueiredo C, Carneiro F, et al. *Helicobacter pylori* genotypes may determine gastric histopathology. *Am J Pathol.* 2001;158(2):647-54. doi: 10.1016/S0002-9440(10)64006-0.
 36. Muñoz-Ramírez ZY, Mendez-Tenorio A, Kato I, et al. Whole genome sequence and phylogenetic analysis show *Helicobacter pylori* strains from Latin America have followed a unique evolution pathway. *Front Cell Infect Microbiol.* 2017;7:50. doi: 10.3389/fcimb.2017.00050.
 37. Ossa H, Aquino J, Pereira R, et al. Outlining the ancestry landscape of Colombian admixed populations. *PLoS One.* 2016;11(10):e0164414. doi: 10.1371/journal.pone.0164414.